Data from a single-center study in Scotland suggested that there were more patients with lung cancer admitted acutely with cancer, non-COVID-19-related illness during the COVID-19 pandemic. “Early and late lockdown […] Read more
Two abstracts presented at the 2020 World Conference on Lung Cancer shed light on how changes in current screening guidelines can influence lung cancer detection rates, specifically among underrepresented populations. […] Read more
Lung Ambition Alliance to award four new Junior Faculty Research Grants. Four early-career researchers have been selected to receive the Lung Ambition Alliance Junior Faculty Grants for the Study of […] Read more
The IASLC has formed an alliance with the Global Lung Cancer Coalition (GLCC), Guardant Health, and AstraZeneca to accelerate the pace of lung cancer survival worldwide. This collaborative effort—known as […] Read more
Oncologists currently have three main therapeutic strategies to choose from when managing patients with advanced NSCLC who lack targetable mutations: immunotherapy alone, immunotherapy-immunotherapy combinations, or immunotherapy-chemotherapy combinations. So how does […] Read more
Amivantamab for Exon 20-Related NSCLC: Excitement in the Patient Community We look forward to Dr. Joshua Sabari’s presentation during the oral abstract presentation session “OA04: new Data from Rare EGFR […] Read more
Read the full articles for detailed summaries of each presentation. TALENT: This national lung cancer screening study conducted in Taiwan in 12,011 individuals, uncovered the presence of lung cancer in […] Read more
Patients with metastatic NSCLC with a PD-L1 tumor proportion score (TPS) ≥ 50% face greater toxicity without the benefit of enhanced efficacy when ipilimumab is combined with pembrolizumab in the […] Read more
LCMC3 Findings Indicate Neoadjuvant Atezolizumab Safe, Efficacious in Resectable Stage IB-IIIB NSCLC
Primary results of the phase II Lung Cancer Mutation Consortium (LCMC) 3 clinical trial suggest that neoadjuvant atezolizumab may be a worthwhile treatment option for selected patients with resectable stage […] Read more
TALENT, a national lung cancer screening study conducted in Taiwan in 12,011 individuals, uncovered the presence of lung cancer in 2.6% of the study population (Abstract PS01.02). These results are […] Read more